185 related articles for article (PubMed ID: 26548355)
1. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
[TBL] [Abstract][Full Text] [Related]
2. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening.
Honjo S; Doran HE; Stiller CA; Ajiki W; Tsukuma H; Oshima A; Coleman MP
Int J Cancer; 2003 Feb; 103(4):538-43. PubMed ID: 12478672
[TBL] [Abstract][Full Text] [Related]
4. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan.
Ajiki W; Tsukuma H; Oshima A; Kawa K
Cancer Causes Control; 1998 Dec; 9(6):631-6. PubMed ID: 10189049
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
6. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
7. Effects of mass screening on age-specific incidence of neuroblastoma.
Bessho F
Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
9. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.
Katanoda K; Hayashi K; Yamamoto K; Sobue T
J Epidemiol; 2009; 19(5):266-70. PubMed ID: 19652443
[TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.
Tajiri T; Souzaki R; Kinoshita Y; Tanaka S; Koga Y; Suminoe A; Matsuzaki A; Hara T; Taguchi T
J Pediatr Surg; 2009 Dec; 44(12):2253-7. PubMed ID: 20006005
[TBL] [Abstract][Full Text] [Related]
11. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan.
Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S
J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors.
Kerbl R; Urban CE; Ambros IM; Dornbusch HJ; Schwinger W; Lackner H; Ladenstein R; Strenger V; Gadner H; Ambros PF
J Clin Oncol; 2003 Nov; 21(22):4228-34. PubMed ID: 14615452
[TBL] [Abstract][Full Text] [Related]
13. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan.
Yamamoto K; Ohta S; Ito E; Hayashi Y; Asami T; Mabuchi O; Higashigawa M; Tanimura M
J Clin Oncol; 2002 Mar; 20(5):1209-14. PubMed ID: 11870162
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of nationwide screening program for neuroblastoma in Japan.
Hisashige A;
Glob J Health Sci; 2014 Apr; 6(4):94-106. PubMed ID: 25001552
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
16. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K
J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry.
Cotterill SJ; Parker L; More L; Craft AW
Med Pediatr Oncol; 2001 Jan; 36(1):231-4. PubMed ID: 11464892
[TBL] [Abstract][Full Text] [Related]
18. Trends in incidence of childhood malignant solid tumors in Japan: Estimation based on hospital-based registration.
Ikeda H; Nakamura Y
J Pediatr Surg; 2015 Sep; 50(9):1506-12. PubMed ID: 25783293
[TBL] [Abstract][Full Text] [Related]
19. Screening of infants and mortality due to neuroblastoma.
Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B
N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470
[TBL] [Abstract][Full Text] [Related]
20. Is neuroblastoma screening evaluation needed and feasible?
Estève J; Parker L; Roy P; Herrmann F; Duffy S; Frappaz D; Lasset C; Hill C; Sancho-Garnier H; Michaelis J
Br J Cancer; 1995 Jun; 71(6):1125-31. PubMed ID: 7779698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]